['Relationship between prostate cancer (PCa) and testosterone (T) is controversial. Conflicting evidence has been published about T levels and development of PCa.', '(1) To determine the relationship between hormone levels and the diagnosis of PCa. (2) To specifically focus on the relationship between PCa and T in men classified as biochemically hypogonadal.', 'Prospective analysis of 1,000 transrectal ultrasound guided prostate biopsies (5\xa0+\xa05 cores biopsies) between September 2007 and January 2010 in one center. Indication for prostate biopsy was suspicion of PCa on the basis of elevated prostate-specific antigen (PSA) and/or digital rectal examination (DRE). Serum testosterone and sex hormones binding globulin (SHBG) were determined in these patients. Of 557 men, the data were sufficient for further analysis. Age, body mass index (BMI), smoking/drinking habits, PSA, free PSA, PSA density, prostate volume, number of previous biopsies, DRE, and hormone levels were prospectively recorded.', 'No relationship was found between T and PCa (449\xa0±\xa0167\xa0ng/dL in PCa versus 437\xa0±\xa0169\xa0ng/dL in non-PCa). SHBG was significantly higher in patients with PCa (51\xa0±\xa027\xa0ng/dL in PCa vs. 44\xa0±\xa018\xa0ng/dL in non-PCa). In hypogonadal men, T levels correlated with the PCa (235\xa0±\xa095\xa0ng/dL in men with PCa versus 270\xa0±\xa058\xa0ng/dL in men without PCa, P\xa0=\xa00.004).'] Is low testosterone bioavailability related to prostate cancer diagnose in patients submitted to prostate biopsy?